{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-098423","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2023-04-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.419448+00:00","generated_at":"2026-06-17T03:11:31.613841+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Mirum reports preliminary Q1 2023 revenue of $31.5M, cash $232.1M; updates VISTAS trial timeline","bullets":["Preliminary Q1 2023 total revenue ~$31.5M, product sales net ~$29M, license revenue ~$2.5M.","Cash, cash equivalents and short-term investments ~$232.1M as of March 31, 2023.","Operating expenses consistent to moderately increased versus Q4 2022.","VISTAS Phase 2b (volixibat in PSC) blinded interim analysis now expected H2 2023.","VANTAGE Phase 2b (PBC) interim and EMBARK Phase 2b (biliary atresia) topline data remain on track for H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-098423","json":"https://secwatch.observer/filing/0001193125-23-098423.json","markdown":"https://secwatch.observer/filing/0001193125-23-098423.md","text":"https://secwatch.observer/filing/0001193125-23-098423.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000119312523098423/0001193125-23-098423-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000119312523098423/d442377d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T03:11:31.613841+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"24658169627650f9db28555d3d23c39b7cb3086f","claim":"Mirum Pharmaceuticals, Inc. reported first quarter of 2023 results: revenue approximately $31.5 million of total revenue, consisting of approximately $29.0 million of product sales, net, and appro.","evidence_excerpt":"The company’s preliminary unaudited financial results for the first quarter of 2023 include: • Approximately $31.5 million of total revenue, consisting of approximately $29.0 million of product sales, net, and approximately $2.5 million of license revenue, for the three months ended March 31, 2023;","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759425/000119312523098423/0001193125-23-098423-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2023"},{"label":"Revenue","value":"approximately $31.5 million of total revenue, consisting of approximately $29.0 million of product sales, net, and appro"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}